Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021-July 2022
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023..
Background: Protection against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 [COVID-19]) can limit transmission and the risk of post-COVID conditions, and is particularly important among healthcare personnel. However, lower vaccine effectiveness (VE) has been reported since predominance of the Omicron SARS-CoV-2 variant.
Methods: We evaluated the VE of a monovalent messenger RNA (mRNA) booster dose against COVID-19 from October 2021 to June 2022 among US healthcare personnel. After matching case-participants with COVID-19 to control-participants by 2-week period and site, we used conditional logistic regression to estimate the VE of a booster dose compared with completing only 2 mRNA doses >150 days previously, adjusted for multiple covariates.
Results: Among 3279 case-participants and 3998 control-participants who had completed 2 mRNA doses, we estimated that the VE of a booster dose against COVID-19 declined from 86% (95% confidence interval, 81%-90%) during Delta predominance to 65% (58%-70%) during Omicron predominance. During Omicron predominance, VE declined from 73% (95% confidence interval, 67%-79%) 14-60 days after the booster dose, to 32% (4%-52%) ≥120 days after a booster dose. We found that VE was similar by age group, presence of underlying health conditions, and pregnancy status on the test date, as well as among immunocompromised participants.
Conclusions: A booster dose conferred substantial protection against COVID-19 among healthcare personnel. However, VE was lower during Omicron predominance, and waning effectiveness was observed 4 months after booster dose receipt during this period. Our findings support recommendations to stay up to date on recommended doses of COVID-19 vaccines for all those eligible.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 10(2023), 10 vom: 06. Okt., Seite ofad457 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Plumb, Ian D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 10.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofad457 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362927618 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362927618 | ||
| 003 | DE-627 | ||
| 005 | 20240210232714.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofad457 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM362927618 | ||
| 035 | |a (NLM)37799130 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Plumb, Ian D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021-July 2022 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023. | ||
| 520 | |a Background: Protection against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 [COVID-19]) can limit transmission and the risk of post-COVID conditions, and is particularly important among healthcare personnel. However, lower vaccine effectiveness (VE) has been reported since predominance of the Omicron SARS-CoV-2 variant | ||
| 520 | |a Methods: We evaluated the VE of a monovalent messenger RNA (mRNA) booster dose against COVID-19 from October 2021 to June 2022 among US healthcare personnel. After matching case-participants with COVID-19 to control-participants by 2-week period and site, we used conditional logistic regression to estimate the VE of a booster dose compared with completing only 2 mRNA doses >150 days previously, adjusted for multiple covariates | ||
| 520 | |a Results: Among 3279 case-participants and 3998 control-participants who had completed 2 mRNA doses, we estimated that the VE of a booster dose against COVID-19 declined from 86% (95% confidence interval, 81%-90%) during Delta predominance to 65% (58%-70%) during Omicron predominance. During Omicron predominance, VE declined from 73% (95% confidence interval, 67%-79%) 14-60 days after the booster dose, to 32% (4%-52%) ≥120 days after a booster dose. We found that VE was similar by age group, presence of underlying health conditions, and pregnancy status on the test date, as well as among immunocompromised participants | ||
| 520 | |a Conclusions: A booster dose conferred substantial protection against COVID-19 among healthcare personnel. However, VE was lower during Omicron predominance, and waning effectiveness was observed 4 months after booster dose receipt during this period. Our findings support recommendations to stay up to date on recommended doses of COVID-19 vaccines for all those eligible | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a healthcare personnel | |
| 650 | 4 | |a vaccine effectiveness | |
| 700 | 1 | |a Mohr, Nicholas M |e verfasserin |4 aut | |
| 700 | 1 | |a Hagen, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Wiegand, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Dumyati, Ghinwa |e verfasserin |4 aut | |
| 700 | 1 | |a Harland, Karisa K |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnadasan, Anusha |e verfasserin |4 aut | |
| 700 | 1 | |a Gist, Jade James |e verfasserin |4 aut | |
| 700 | 1 | |a Abedi, Glen |e verfasserin |4 aut | |
| 700 | 1 | |a Fleming-Dutra, Katherine E |e verfasserin |4 aut | |
| 700 | 1 | |a Chea, Nora |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Barter, Devra |e verfasserin |4 aut | |
| 700 | 1 | |a Brackney, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Fridkin, Scott K |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Lucy E |e verfasserin |4 aut | |
| 700 | 1 | |a Lovett, Sara A |e verfasserin |4 aut | |
| 700 | 1 | |a Ocampo, Valerie |e verfasserin |4 aut | |
| 700 | 1 | |a Phipps, Erin C |e verfasserin |4 aut | |
| 700 | 1 | |a Marcus, Tiffanie M |e verfasserin |4 aut | |
| 700 | 1 | |a Smithline, Howard A |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Peter C |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Lilly C |e verfasserin |4 aut | |
| 700 | 1 | |a Moran, Gregory J |e verfasserin |4 aut | |
| 700 | 1 | |a Krebs, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Steele, Mark T |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Stephen C |e verfasserin |4 aut | |
| 700 | 1 | |a Schrading, Walter A |e verfasserin |4 aut | |
| 700 | 1 | |a Chinnock, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Beiser, David G |e verfasserin |4 aut | |
| 700 | 1 | |a Faine, Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Haran, John P |e verfasserin |4 aut | |
| 700 | 1 | |a Nandi, Utsav |e verfasserin |4 aut | |
| 700 | 1 | |a Chipman, Anne K |e verfasserin |4 aut | |
| 700 | 1 | |a LoVecchio, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Talan, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Pilishvili, Tamara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 10(2023), 10 vom: 06. Okt., Seite ofad457 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:10 |g day:06 |g month:10 |g pages:ofad457 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofad457 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 10 |b 06 |c 10 |h ofad457 | ||